GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acelyrin Inc (NAS:SLRN) » Definitions » Cyclically Adjusted Price-to-FCF

Acelyrin (Acelyrin) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Acelyrin Cyclically Adjusted Price-to-FCF?

Acelyrin does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate Cyclically Adjusted Price-to-FCF for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Acelyrin Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Acelyrin's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acelyrin Cyclically Adjusted Price-to-FCF Chart

Acelyrin Annual Data
Trend Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
- - -

Acelyrin Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acelyrin's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Acelyrin's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acelyrin's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acelyrin's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Acelyrin's Cyclically Adjusted Price-to-FCF falls into.



Acelyrin Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Acelyrin does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate Cyclically Adjusted Price-to-FCF for this company.


Acelyrin  (NAS:SLRN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Acelyrin Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Acelyrin's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Acelyrin (Acelyrin) Business Description

Industry
Traded in Other Exchanges
N/A
Address
4149 Liberty Canyon Road, Agoura Hills, CA, USA, 91301
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates.
Executives
Shao-lee Lin director, officer: Chief Executive Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Gil M Labrucherie officer: Interim CFO 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Beth C Seidenberg director, 10 percent owner
Henry O Gosebruch director 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Mardi Dier officer: CFO and CBO C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Mina Kim officer: Chief Legal & Admin. Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Ronald Oyston officer: Chief People Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Paul Peloso officer: Chief Medical Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Daniel J. Becker director C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036
Westlake Biopartners Fund Ii, L.p. 10 percent owner 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361
Ayurmaya Capital Management Company, Lp director, 10 percent owner, other: See Remarks 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Sean E Harper 10 percent owner AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Melanie Gloria officer: Chief Operating Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Westlake Biopartners Gp Ii, Llc 10 percent owner 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361

Acelyrin (Acelyrin) Headlines

From GuruFocus

ACELYRIN INVESTOR DEADLINE APPROACHING

By PRNewswire 01-11-2024